CHAPTER I Data collection in expanded access: real-world examples Adapted from: Pritelivir for the treatment of resistant HSV infections in immunocompromised patients: update on an ongoing Phase 3 trial and Early Access Program Birkmann A, Marini A, Müller A, Polak TB, Rangaraju M, Sumner M, Trübel H, Wald A, Zimmermann H. STI & HIV, 2023 Chicago (Oral) Immunocompromised patients with Resistant HSV Infections: Results of the International Early Access Program of Pritelivir Avery RK, Polak TB, Birkmann A, Truebel H, Gunson S, Sumner M, Dickter J, Neofytos D, and Lee Y. SSAI/ICHS, 2022 Basel (Poster) Demographics and Treatment Outcomes in Patients with EBV+ PTLD Treated with Off-the-Shelf EBVspecific CTL (Tabelecleucel) Under an Ongoing Expanded Access Program in Europe: First Analyses Choquet S, Uttenthal B, Chaganti S, Comoli P, Trappe RU, Friedetzky A, Xing B, Li X, Polak TB, Gamelin L, Terwey J-H, and Dierickx D. EHA and ASCO, 2022 Vienna, Chicago (Posters)
RkJQdWJsaXNoZXIy MTk4NDMw